Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From the Chinese HARMONY Cohort
Authors' conclusion
In routine clinical care, lower doses of semaglutide were associated with clinically meaningful 24-week weight loss in Chinese adults with obesity.
Study context
- Population
- Chinese adults with obesity, HARMONY real-world cohort143 at wk 12
- Outcome
- Percentage change in body weight from baseline
- Follow-up
- Weeks 12 and 24
Methodological detailsreal-world, routine care
- Real-world
- Routine care
Main finding
As reported in the abstract
Mean % change in body weight from baseline
Mean percent weight change at week 12 (143 participants)
−7.3%
Mean percent weight change at week 24 (113 participants)
−9.9%
Observational data: associations, not effects.
Further findings
Type 2 diabetes vs without diabetes
| Outcome | Type 2 diabetes | Without diabetes | P value |
|---|---|---|---|
| % weight change by baseline T2D status · week 24 | −7.4% | −12.4% | P < 0.001 |
With intrapancreatic fat deposition (IPFD) vs without IPFD
| Outcome | With IPFD | Without IPFD | P value |
|---|---|---|---|
| % weight change by baseline intrapancreatic fat deposition (IPFD) · week 24 | −9.0% | −11.6% | P = 0.043 |
Mean absolute weight loss · weeks 12 and 24
kg
- Mean absolute weight loss at week 12
- 6.7
- Mean absolute weight loss at week 24
- 9.1
≥5% weight loss · week 24
- Participants achieving 5% weight loss or more
- 76.1%
Original publication
Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From the Chinese HARMONY Cohort. Diabetes Obes Metab. Published 15 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →